Controversies in Hyperkalaemia Management and Practical Approaches
Published: 20 January 2022
Controversy is good. But when it comes to hyperkalaemia management, we need solutions.
Chair, Prof Sydney Tang (University of Hong Kong, HK) Prof Chuan-Ming Hao (Huashan Hospital, CN) and Dr Kieran McCafferty (Queen Mary University London, UK) discuss the implementation of hyperkalaemia management strategies for patients with CKD in line with recent guidelines updates.
The objectives of this educational symposium are to:
- Highlight the burden associated with hyperkalaemia and the impact this has on the use of guideline-directed medical therapy for the treatment of CKD
- Outline the recent updates to KDIGO guidelines around the use of potassium binders to optimise RAASi
- Explain how guideline recommendations can be translated to daily clinical practice
More from this programme
Controversies in Hyperkalaemia Management
New guidelines: Advice for managing RAASi in patients with Hyperkalaemia
Managing Hyperkalaemia in the real world today: A case-based study
Professor Sydney Tang is currently Chair of Renal Medicine and Yu Professor in Nephrology at the University of Hong Kong. He underwent training in nephrology in Hong Kong and in basic research at King’s College London, UK, and the University of Washington, USA.
Professor Tang’s research interests revolve around pathogenetic mechanisms underlying diabetic and proteinuric kidney disease, and the treatment of immunoglobulin A nephropathy.
Professor Tang is the President-elect of the Asian Pacific Society of Nephrology,an Executive Committee member of Kidney Disease: Improving Global Outcomes, Deputy Chair of the Continuing Medical Education Committee, member of the Saving Young Lives Committee and Education Work Group and an N&E Asia Regional Board member of the International Society of Nephrology, and an International Honorary Member of the Japanese Society of Nephrology. He is a past Chairman of the Hong Kong Society of Nephrology and serves the Hong Kong…